Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 251

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

Open access
Lipson, David A., Crim, Courtney, Criner, Gerard J., Day, Nicola C., Dransfield, Mark T., Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kilbride, Sally, Lange, Peter, Lomas, David A., Lettis, Sally, Manchester, Pamela, Martin, Neil, Midwinter, Dawn, Morris, Andrea, Pascoe, Steven J., Singh, Dave, Wise, Robert A., Martinez, Fernando J. · 2020 · American Journal of Respiratory and Critical Care Medicine

Abstract

Abstract Rationale The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease (COPD) at risk of future exacerbations. Five hundred seventy-four patients were censored in the original analysis owing to incomplete vital status information. Objectives Report ACM and impact of stepping down therapy, following collection of additional vital status data. Methods Patients were randomized 2:2:1 to FF/UMEC/VI 100/62.5/25 μg, FF/VI 100/25 μg, or UMEC/VI 62.5/25 μg following a run-in on their COPD therapies. Time to ACM was prespecified. Additional vital status data collection and subsequent analyses were performed post hoc. Measurements and Main Results We report vital status data for 99.6% of the intention-to-treat population (n = 10,355), documenting 98 (2.36%) deaths on FF/UMEC/VI, 109 (2.64%) on FF/VI, and 66 (3.19%) on UMEC/VI. For FF/UMEC/VI, the hazard ratio for death was 0.72 (95% confidence interval, 0.53–0.99; P = 0.042) versus UMEC/VI and 0.89 (95% confidence interval, 0.67–1.16; P = 0.387) versus FF/VI. Independent adjudication confirmed lower rates of cardiovascular and respiratory death and death associated with the patient’s COPD. Conclusions In this secondary analysis of an efficacy outcome from the IMPACT trial, once-daily single-inhaler FF/UMEC/VI triple therapy reduced the risk of ACM versus UMEC/VI in patients with symptomatic COPD and a history of exacerbations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201911-2207oc

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 251

Metadata

Authors
Lipson, D. A., Crim, C., Criner, G. J., Day, N. C., Dransfield, M. T., Halpin, D. M. G., Han, M. K., Jones, C. E., Kilbride, S., Lange, P., Lomas, D. A., Lettis, S., Manchester, P., Martin, N., Midwinter, D., Morris, A., Pascoe, S. J., Singh, D., Wise, R. A., & Martinez, F. J.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2020-06-15
Volume
201
Issue
12
Pages
1508-1516
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W3011621519
Cited by
251
References
3
FWCI
18.72
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. https://app.cochat.ai/papers/10.1164/rccm.201911-2207oc
The paper
Lipson, D. A., Crim, C., Criner, G. J., Day, N. C., Dransfield, M. T., Halpin, D. M. G., Han, M. K., Jones, C. E., Kilbride, S., Lange, P., Lomas, D. A., Lettis, S., Manchester, P., Martin, N., Midwinter, D., Morris, A., Pascoe, S. J., Singh, D., Wise, R. A., & Martinez, F. J. (2020). Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201911-2207oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.